Ovarian Hyperstimulation Syndrome – It’s Time to Reverse the Trend
By Dr. Geeta Nargund | BioNews | Dec. 5, 2016
In this commentary, Dr. Geeta Nargund, medical director at CREATE Fertility, discusses the increase in ovarian hyperstimulation syndrome (OHSS) reported by fertility clinics in the United Kingdom.
In the author’s opinion, the Human Fertilization and Embryology Authority (HFEA) report “obfuscates” the real data – a 40 percent rise in hospital admissions with severe OHSS. She suggests the HFEA prioritize this “alarming statistic” and focus on reversing the trend.
Some of Nargund’s recommendations include: a reduced dose of stimulation followed by GnRH agonist to trigger ovulation, with an option of cryopreservation of all embryos; and abandoning the use of the “long downregulation” protocol, employed in many IVF treatment cycles, and a switch to antagonist cycles.
In line with others in the field, Nargund also emphasizes the need for informed consent – placing the responsibility for this on providers – and rigorous documentation of the effects of stimulation protocols (including the drugs and dosages used).